Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
PARSIPPANY, N.J., May 01, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences:
- Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET
- Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET)
A live audio webcast of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcasts will be archived on the Pacira website for two weeks following the presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti (973) 254-4387 [email protected]
